echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily: the listing application of pribalin sustained release tablets of Ted pharmaceutical was undertaken

    Research and development daily: the listing application of pribalin sustained release tablets of Ted pharmaceutical was undertaken

    • Last Update: 2020-01-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The application for marketing of tyde Pharma pregabalin sustained release tablets was undertaken; the new indications of Zhengda Tianqing androtinib hydrochloride capsule are to be reviewed preferentially; the new lymphoma drug umbralisib is to be listed in the United States; the special proteins related to ovarian cancer may promote the occurrence of Alzheimer's disease We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel On September 19, Beijing Taide Pharmaceutical Co., Ltd submitted an application for listing of three new categories of "pregabalin sustained release tablets", which was undertaken by nmpa (acceptance No.: cyhs2000085) Recently, the marketing application of enmetrazumab for Roche injection (acceptance No.: jxss1900012 / 13) was in the state of "in approval" in nmpa After data supplement, it is expected to be approved as the first ADC drug to be listed in China Recently, the State Drug Administration updated the processing status of Romer her2-adc (ADO trastuzumab emtansine, trade name kadcyla ®) to "under approval", which is expected to be approved for listing in the near future Recently, cost regulators in England and Germany rejected Bayer's application for the listing of vitrakvi (larotrecinib), mainly due to the high price of the drug and the limitations of clinical data CDE announced a new batch of applications to be included in the priority review and approval list, including the listing application for the fourth new indication of Zhengda Tianqing androtinib hydrochloride capsule Recently, precision Biosciences announced that the U.S Food and Drug Administration (FDA) approved the application of research new drug (ind) for pbcar269a therapy, and awarded the title of orphan drug for the therapy Recently, TG therapeutics announced that it has started rolling application for new drugs to FDA, seeking to accelerate the approval of umbralisib, a dual effect inhibitor of inositol-3-kinase δ and CK1 - ε, which has been taken orally by TG therapeutics once a day, for patients with borderline lymphoma and follicular lymphoma who have been previously treated Recently, neurelis company announced that the FDA has approved valtoco as an acute treatment drug to treat the intermittent and stereotyped frequent seizure activities of epilepsy patients aged 6 years and over, which is different from the normal seizure mode of patients On June 16, Shanghai Zesheng Pharmaceutical Co., Ltd changed the listing application of Newland green, a recombinant human for injection, into the "in approval" state, indicating that the international first genetic engineering biological innovative drug for chronic heart failure treatment is expected to be approved for listing in China Recently, scientists from Houston Methodist cancer center and other institutions identified a special protein in ovarian cancer, which may promote the decline of brain function and the development of Alzheimer's disease.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.